TRIPHENYLENE DERIVATIVES FOR USE IN IMAGING BIOLOGICAL TISSUE OR FLUID

    公开(公告)号:WO2021058969A1

    公开(公告)日:2021-04-01

    申请号:PCT/GB2020/052324

    申请日:2020-09-24

    Abstract: A composition for imaging a biological tissue or fluid comprising a compound of formula (A) and a biologically acceptable diluent or carrier, (A) wherein X represents one of a nitrogen atom, an oxygen atom, a sulphur atom, a phosphorus atom, or a selenium atom; R represents an aromatic group and/or an aliphatic group; p is an integer of 1 to 2; q and s are independently integers of 1, 2, 3, or 4; Y1, Y2, and Y3 independently represent a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, a polyglycol group, an oxygen atom, a nitrogen atom, a cyano group, a nitro group; and/or wherein two or more of Y1, Y2, and Y3 may combine together to form a condensed ring.

    COMPOSITIONS AND METHODS FOR TREATING CHRONIC URTICARIA
    2.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING CHRONIC URTICARIA 审中-公开
    用于治疗慢性尿道的组合物和方法

    公开(公告)号:WO2015023790A1

    公开(公告)日:2015-02-19

    申请号:PCT/US2014/050951

    申请日:2014-08-13

    CPC classification number: A61K31/428 A61K45/06 C07D277/60

    Abstract: Disclosed herein are methods of treating conditions, which may be associated with elevated levels of mast cells, basophils, eosinophils, or a combination thereof, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.

    Abstract translation: 本文公开了治疗条件的方法,其可以与治疗有效量的右丙吡酮或其药学上可接受的盐与肥大细胞,嗜碱性粒细胞,嗜酸性粒细胞或其组合的水平升高相关。

    共役系化合物、含窒素縮合環化合物、含窒素縮合環重合体、有機薄膜及び有機薄膜素子
    4.
    发明申请
    共役系化合物、含窒素縮合環化合物、含窒素縮合環重合体、有機薄膜及び有機薄膜素子 审中-公开
    连结化合物,氮化聚合环化合物,氮化聚合物聚合物,有机薄膜和有机薄膜元件

    公开(公告)号:WO2009069687A1

    公开(公告)日:2009-06-04

    申请号:PCT/JP2008/071520

    申请日:2008-11-27

    Abstract:  第一の発明群においては、下記一般式(I)で表される基又は下記一般式(II)で表される基を2以上有する共役系化合物を提供する。 [式中、Ar及びAr’のいずれか一方は炭素数6以上の2価の芳香族炭化水素基、他方は炭素数4以上の2価の複素環基(これらの基は置換基を有してもよい。但し、これらの基全体としてフッ素原子を含有しない)を示し、R 1 及びR 2 はそれぞれ独立に、水素原子、ハロゲン原子又は1価の基、Ar’’は、3価の芳香族炭化水素基又は3価の複素環基をそれぞれ示す。但し、共役系化合物が、一般式(I)で表される基を2以上有する場合は、当該基以外の部分はフッ素原子を含有しない。]  第二の発明群においては、下記一般式(α-I)で表される含窒素縮合環化合物を提供する。 [式(α-I)中、R 21 及びR 22 は各々独立に、水素原子、ハロゲン原子又は置換基で置換されていてもよい1価の基を示し、Z 21 及びZ 22 は各々独立に、下記式(α-i)~(α-ix)で表される基のいずれかを示す。 [式中、R 23 、R 24 、R 25 及びR 26 は各々独立に、水素原子、ハロゲン原子又は1価の基を示し、R 23 とR 24 とは互いに結合して環を形成していてもよい。なお、式(α-viii)で表される基は左右反転していてもよい。]

    Abstract translation: 公开了具有两个或更多个由通式(I)或(II)表示的基团的共轭化合物。 (I)(II)其中Ar和Ar'中的一个表示具有6个以上碳原子的二价芳香族烃基,另一个表示具有4个以上碳原子的2价杂环基(这些基团可以具有取代基) 条件是每个基团在其整个结构中不含氟原子); R1和R2独立地表示氢原子,卤素原子或一价基团; Ar“表示三价芳香族烃基或三价杂环基, 条件是当共轭化合物具有两个或更多个由通式(I)表示的基团时,除基团之外的共轭化合物的部分不含氟原子。 还公开了由通式(a-I)表示的氮化稠环化合物。 (a-I)其中R 21和R 22独立地表示氢原子,卤素原子或可被取代基取代的一价基团; Z21和Z22独立地表示由选自式(a-i)至(a-ix)的任何一个式表示的基团。 (a-vi)(a-vi)(a-vi)(a-vi)(a-vi)(a-vi)(a-vi) 表示氢原子,卤素原子或一价基团,R 23和R 24可以一起形成环; 并且由式(a-viii)表示的基团可以从左向右翻转。

    MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-?B ACTIVITY AND USE THEREOF
    5.
    发明申请
    MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-?B ACTIVITY AND USE THEREOF 审中-公开
    糖皮质激素受体,AP-1和/或NF-κB活性的调节剂及其用途

    公开(公告)号:WO2008057862A3

    公开(公告)日:2008-10-16

    申请号:PCT/US2007083094

    申请日:2007-10-31

    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I) an enantiomer, diastereomer, tautomer, solvate (e.g. a hydrate), or a pharmaceutically-acceptable salt, thereof, wherein: M is selected from alkyl, substituted alkyl, cycloalkyl, aryl, heterocyclo, and heteroaryl, provided that if M is alkyl then R 6 and R 7 taken together with the carbon atom to which they are both attached are selected from a group other than cycloalkyl; Q is selected from (i) hydrogen, C 1 -C 4 alkyl, and substituted C 1 -C 4 alkyl; or (ii) Q and R 6 are combined with the carbon atoms to which they are attached to form a 3- to 6-membered cycloalkyl; or (iii) Q and M a M are combined with the carbon atom(s) to which they are attached to form a 3- to 7-membered ring containing 1-2 heteroatoms which are independently selected from the group consisting of O, S, SO 2 , and N which ring may be optionally substituted with 0-2 R 5 groups or carbonyl; Z is selected from cycloalkyl, heterocyclo, aryl, or heteroaryl; and M a , Z a , R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 22 are as defined herein. Also provided are pharmaceutical compositions and methods of treating metabolic and inflammatory- or immune-associated diseases or disorders using said compounds.

    Abstract translation: 提供了新颖的非类固醇化合物,其用于治疗与糖皮质激素受体,AP-1和/或NF-κB活性的调节相关的疾病,包括具有式(I)结构的炎性和免疫疾病,肥胖症和糖尿病, 其中:M选自烷基,取代的烷基,环烷基,芳基,杂环基和杂芳基,条件是如果M是烷基,则M是烷基,取代的烷基,环烷基, R 6和R 7与它们都连接的碳原子一起选自除环烷基以外的基团; Q选自(i)氢,C 1 -C 4烷基和取代的C 1 -C 4 SUB 烷基; 或(ii)Q和R 6与它们所连接的碳原子结合形成3至6元环烷基; 或(iii)Q和MASS a M与它们所连接的碳原子结合形成含有1-2个独立选自以下的杂原子的3-至7-元环: 由O,S,SO 2,N和N组成的组,该环可以任选地被0-2个R 5基团或羰基取代; Z选自环烷基,杂环基,芳基或杂芳基; 和 a ,Z a 1 2 3 ,R 4,R 6,R 7,和R 22如本文所定义。 还提供了使用所述化合物治疗代谢和炎症或免疫相关疾病或病症的药物组合物和方法。

    NOVEL AZABICYCLIC RING AMMONIUMS AND THEIR USE FOR TREATING PROTEIN AGING DISEASE

    公开(公告)号:WO2006034605A1

    公开(公告)日:2006-04-06

    申请号:PCT/CN2004/001119

    申请日:2004-09-28

    CPC classification number: C07D277/64 C07D263/52 C07D277/60

    Abstract: The present invention relates to azabicyclic ring ammoniums of general formula I in which the definition of each radical is described in the specification and/or their pharmaceutically acceptable salts and hydrates; pharmaceutical compositions comprising the same, also to the uses of those compositions for the preparation of medicaments for (i) improving the elasticity or reducing wrinkles of the skin, (ii) treating diabetes, (iii) treating or ameliorating adverse sequelae of diabetes, (iv) treating or ameliorating kidney damage, (v) treating or ameliorating blood vasculature, (vi) treating or ameliorating hypertension, (vii) treating or ameliorating retinopathy, (viii) treating or ameliorating damage to lens proteins, (ix) treating or ameliorating cataracts, (x) treading or ameliorating peripheral neuropathy, (xi) treating or ameliorating osteoarthritis, or use for the preparation of a buccal medicament for preventing or reversing the staining of teeth, or the use for the preparation of various freshness keeper for crops plant protein, animal protein.

    POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS
    10.
    发明申请
    POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS 审中-公开
    多环芳烃噻唑烷-2-亚基AMINES,其制造方法相同,它们作为药物

    公开(公告)号:WO00004006A1

    公开(公告)日:2000-01-27

    申请号:PCT/EP1999/004644

    申请日:1999-07-03

    CPC classification number: C07D277/60 C07D417/04 C07D513/04

    Abstract: The invention relates to polycyclic thiazolidin-2-ylidene amines and the physiologically acceptable salts and physiologically functional derivatives thereof. Disclosed are polycyclic thiazolidin-2-ylidene amines of formula (I), wherein the radicals mentioned have the meanings as cited. The invention also relates to the physiologically acceptable salts and to a method of production thereof. The compounds can be used as anoretics.

    Abstract translation: 本发明涉及多环的噻唑烷-2-亚基胺和它们的生理学上可接受的盐和生理学功能衍生物。 有式(I)的多环噻唑烷-2-亚基胺,其中的基团具有所述的含义,并描述它们的生理学可耐受的盐和它们的制备过程。 的化合物是合适的,例如,是 作为食欲抑制剂。

Patent Agency Ranking